

Analysis of Beta-lactam Resistance Mechanisms in Clinical E. coli Isolates

Introduction:

The increasing prevalence of antimicrobial resistance (AMR) in Escherichia coli poses a significant challenge in clinical settings. This study aimed to analyze the resistance mechanisms in five E. coli isolates, focusing on penicillin-binding proteins (PBPs), β -lactamase genes, and efflux-mediated resistance. Notably, NDM-5 indicates high-level resistance to carbapenems, a class of last-resort antibiotics. The findings help understand the genetic basis of resistance, particularly to beta-lactams, aiding in clinical decision-making for effective treatment strategies.

Methods:

- **Genome Annotation:** The genomes were annotated using Prokka.
- **PBP Gene Extraction:** Key penicillin-binding protein genes (PBP1a, PBP1b, PBP2, PBP3, PBP4, PBP5, PBP6, PBP7) were extracted using Biopython.
- **Multiple Sequence Alignment (MSA):** PBP sequences were aligned against the wild-type reference to identify mutations.
- **ResFinder & RGI (CARD) Analysis:** AMR gene detection and phenotypic resistance prediction were performed.
- **Antibiotic Sensitivity Testing (AST):** Resistance profiles were analyzed for β -lactams and other antibiotic classes.

Results:

Isolate Description

All five isolates were Escherichia coli, exhibiting multidrug resistance, with a strong focus on β -lactam resistance.

Key Findings from PBP Analysis

- In all isolates, an insertion mutation (**ATTA**ACTATCGA) was identified in **PBP3**, correlating with resistance to **aztreonam** and **avibactam**.
- Other mutations in PBPs were also observed, potentially contributing to altered β -lactam binding.

pbp3_reference	GGCGTGGTGCGGGA AAAACTCGGTACTCAATACCATTCCTTATCGA -----AT	1008
pbp3_extracted	GGCGTGGTGCGGGA AAAACTCGGTACTCAATACCATTCCTTATCGA ATTA ACTATCGAAT	1020
	*****	***

β-lactamase Enzymes Identified (ResFinder & CARD RGI Results):

Gene	Resistance to	Mechanism
blaNDM-5	Carbapenems, cephalosporins, penicillins	Metallo-Beta-Lactamase (MBL) hydrolyses Beta lactams
blaCMY-42	Extended-spectrum cephalosporins, penicillins	AmpC beta-lactamase production
blaTEM-1B	Penicillins, aminopenicillins	Hydrolyzes narrow spectrum beta-lactams but not ESBL
blaCTX-M-15	Cephalosporins	Extended-spectrum Beta-lactamase (ESBL)

Cultural Sensitivity Report & Resistance Profile:

sample_id	Zone	Specimen_coll	Ertapenem	Imipenem	Meropenem	Ceftazidime	Ceftriaxone	Cefepime	Aztreonam	icillin.Clavulani	azidime.Avi	bacracillin.Tazobactam	
EC031	Northern	blood	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	
EC040	Northern	blood	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	
ECBN29	Western	blood	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant		Resistant	
ECBN31	Western	blood	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant		Resistant	
ECBN32	Western	blood	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant	Resistant		Resistant	

Conclusion:

This study confirms the presence of CTX-M, TEM β-lactamases, NDM-5, CMY-42 β-lactamases, PBP3 mutations, and efflux-mediated resistance as primary drivers of β-lactam resistance in these E. coli isolates. The findings suggest that standard β-lactam treatments may be ineffective, necessitating alternative therapeutic strategies. Further clinical correlation is advised to optimize treatment outcomes.